LifeSteps Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

LifeSteps Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.3K	Buy	+47	New	+$20.8K	0.01%	288

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

LifeSteps Financial's VRTX Position: Q2 2026 in Review

LifeSteps Financial opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 47 shares worth $23.3K. The stake represents 0.01% of the portfolio and ranks #288 among its holdings.

685 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

LifeSteps Financial held 47 shares of Vertex Pharmaceuticals worth $23.3K as of Q2 2026.
Vertex Pharmaceuticals was a new LifeSteps Financial position in Q2 2026.
Vertex Pharmaceuticals made up 0.01% of LifeSteps Financial's portfolio in Q2 2026, its #288 holding.
685 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on LifeSteps Financial's 13F filing for Q2 2026, filed 17 Jul 2026.